MedTrace Logo

A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in Human

NCT05836805 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-05-01

No results posted yet for this study

Summary

This non-randomized, single group, open-label study will investigate the mass balance, routes of elimination, pharmacokinetics, metabolism, safety and tolerability of a single oral dose of \[14C\]XZP-3621 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C]XZP-3621

Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)

Sponsors & Collaborators

  • Xuanzhu Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Liyan Miao, DPH · First Affiliated Hospital of Suzhou Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2023-08-31
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05836805 on ClinicalTrials.gov